The University of Chicago Header Logo

Connection

Ayman Al-Hendy to Uterine Neoplasms

Back to Details
This is a "connection" page, showing publications Ayman Al-Hendy has written about Uterine Neoplasms.
Ayman Al-Hendy
Connection Strength
39.093
Uterine Neoplasms
  1. Empowering Strategies for Lifestyle Interventions, Diet Modifications, and Environmental Practices for Uterine Fibroid Prevention; Unveiling the LIFE UP Awareness. Nutrients. 2024 Mar 12; 16(6).
    View in: PubMed
    Score: 0.732
  2. Survivin-Sodium Iodide Symporter Reporter as a Non-Invasive Diagnostic Marker to Differentiate Uterine Leiomyosarcoma from Leiomyoma. Cells. 2023 12 13; 12(24).
    View in: PubMed
    Score: 0.720
  3. Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach). Int J Mol Sci. 2023 Nov 04; 24(21).
    View in: PubMed
    Score: 0.714
  4. Current and Emerging Treatment Options for Uterine Fibroids. Drugs. 2023 Dec; 83(18):1649-1675.
    View in: PubMed
    Score: 0.714
  5. The combination of natural compounds Crila and epigallocatechin gallate showed enhanced antiproliferative effects on human uterine fibroid cells compared with single treatments. F S Sci. 2023 11; 4(4):341-349.
    View in: PubMed
    Score: 0.708
  6. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023 12; 229(6):662.e1-662.e25.
    View in: PubMed
    Score: 0.706
  7. GnRH agonists and antagonists in therapy of symptomatic uterine fibroids - current roles and future perspectives. Expert Opin Pharmacother. 2023 Sep-Dec; 24(16):1799-1809.
    View in: PubMed
    Score: 0.705
  8. Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy). Adv Ther. 2023 10; 40(10):4127-4133.
    View in: PubMed
    Score: 0.703
  9. A plain language summary of the long-term relugolix combination therapy study for uterine fibroids. J Comp Eff Res. 2023 08; 12(8):e230069.
    View in: PubMed
    Score: 0.700
  10. Epigenetic Modulation of Inflammatory Pathways in Myometrial Stem Cells and Risk of Uterine Fibroids. Int J Mol Sci. 2023 Jul 19; 24(14).
    View in: PubMed
    Score: 0.700
  11. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial. F S Sci. 2023 Nov; 4(4):317-326.
    View in: PubMed
    Score: 0.699
  12. A plain language summary of the safety of relugolix combination therapy and improvement in symptoms in women with uterine fibroids from the LIBERTY 1 and LIBERTY 2 studies. Pain Manag. 2023 Apr; 13(4):205-211.
    View in: PubMed
    Score: 0.691
  13. EZH2 activates Wnt/ß-catenin signaling in human uterine fibroids, which is inhibited by the natural compound methyl jasmonate. F S Sci. 2023 08; 4(3):239-256.
    View in: PubMed
    Score: 0.691
  14. The Functional Role and Regulatory Mechanism of FTO m6A RNA Demethylase in Human Uterine Leiomyosarcoma. Int J Mol Sci. 2023 Apr 27; 24(9).
    View in: PubMed
    Score: 0.689
  15. Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics. Cells. 2023 04 09; 12(8).
    View in: PubMed
    Score: 0.687
  16. Update on the Role and Regulatory Mechanism of Extracellular Matrix in the Pathogenesis of Uterine Fibroids. Int J Mol Sci. 2023 Mar 17; 24(6).
    View in: PubMed
    Score: 0.684
  17. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials. Am J Obstet Gynecol. 2023 03; 228(3):320.e1-320.e11.
    View in: PubMed
    Score: 0.667
  18. Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas. Obstet Gynecol. 2022 12 01; 140(6):920-930.
    View in: PubMed
    Score: 0.666
  19. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022 07 13; 43(4):678-719.
    View in: PubMed
    Score: 0.652
  20. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells. 2022 07 10; 11(14).
    View in: PubMed
    Score: 0.652
  21. Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials. Obstet Gynecol. 2022 06 01; 139(6):1070-1081.
    View in: PubMed
    Score: 0.643
  22. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. Expert Opin Pharmacother. 2022 Mar; 23(4):421-429.
    View in: PubMed
    Score: 0.632
  23. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids. Expert Opin Drug Saf. 2022 Apr; 21(4):477-486.
    View in: PubMed
    Score: 0.620
  24. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
    View in: PubMed
    Score: 0.618
  25. Treatment of Uterine Fibroid Symptoms with Relugolix Combination Therapy. N Engl J Med. 2021 02 18; 384(7):630-642.
    View in: PubMed
    Score: 0.592
  26. The Significance of Measuring Vitamin D Serum Levels in Women with Uterine Fibroids. Reprod Sci. 2021 08; 28(8):2098-2109.
    View in: PubMed
    Score: 0.579
  27. Vitamins and Uterine Fibroids: Current Data on Pathophysiology and Possible Clinical Relevance. Int J Mol Sci. 2020 Aug 01; 21(15).
    View in: PubMed
    Score: 0.570
  28. Molecular Bio-Imaging Probe for Non-Invasive Differentiation Between Human Leiomyoma Versus Leiomyosarcoma. Reprod Sci. 2020 02; 27(2):644-654.
    View in: PubMed
    Score: 0.548
  29. Vitamin D and uterine fibroids: preclinical evidence is in; time for an overdue clinical study! Fertil Steril. 2020 01; 113(1):89-90.
    View in: PubMed
    Score: 0.547
  30. Simvastatin and uterine fibroids: opportunity for a novel therapeutic option. Fertil Steril. 2018 12; 110(7):1272-1273.
    View in: PubMed
    Score: 0.508
  31. Endocrine disruptor exposure during development increases incidence of uterine fibroids by altering DNA repair in myometrial stem cells. Biol Reprod. 2018 10 01; 99(4):735-748.
    View in: PubMed
    Score: 0.502
  32. Uterine fibroid therapy: the pharmacokinetic considerations. Expert Opin Drug Metab Toxicol. 2018 Sep; 14(9):887-889.
    View in: PubMed
    Score: 0.496
  33. Expanding upon the Human Myometrial Stem Cell Hypothesis and the Role of Race, Hormones, Age, and Parity in a Profibroid Environment. Am J Pathol. 2018 10; 188(10):2293-2306.
    View in: PubMed
    Score: 0.496
  34. Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 03; 131(3):431-439.
    View in: PubMed
    Score: 0.482
  35. Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 02; 13(2):169-177.
    View in: PubMed
    Score: 0.475
  36. Uterine Leiomyoma: New Perspectives on an Old Disease. Semin Reprod Med. 2017 11; 35(6):471-472.
    View in: PubMed
    Score: 0.471
  37. Uterine Fibroids: Burden and Unmet Medical Need. Semin Reprod Med. 2017 11; 35(6):473-480.
    View in: PubMed
    Score: 0.471
  38. Origin of Uterine Fibroids: Conversion of Myometrial Stem Cells to Tumor-Initiating Cells. Semin Reprod Med. 2017 11; 35(6):481-486.
    View in: PubMed
    Score: 0.471
  39. Silencing Med12 Gene Reduces Proliferation of Human Leiomyoma Cells Mediated via Wnt/ß-Catenin Signaling Pathway. Endocrinology. 2017 03 01; 158(3):592-603.
    View in: PubMed
    Score: 0.450
  40. Estrogen Receptors and Signaling in Fibroids: Role in Pathobiology and Therapeutic Implications. Reprod Sci. 2017 09; 24(9):1235-1244.
    View in: PubMed
    Score: 0.441
  41. Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids. Reprod Sci. 2016 10; 23(10):1314-25.
    View in: PubMed
    Score: 0.422
  42. Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril. 2016 06; 105(6):1638-1648.e8.
    View in: PubMed
    Score: 0.421
  43. Targeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma. Reprod Sci. 2016 Apr; 23(4):464-74.
    View in: PubMed
    Score: 0.418
  44. Vitamin D3 Inhibits Wnt/ß-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells. J Clin Endocrinol Metab. 2016 04; 101(4):1542-51.
    View in: PubMed
    Score: 0.417
  45. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development. Reprod Sci. 2016 Feb; 23(2):163-75.
    View in: PubMed
    Score: 0.396
  46. 1,25-dihydroxyvitamin D3 regulates expression of sex steroid receptors in human uterine fibroid cells. J Clin Endocrinol Metab. 2015 Apr; 100(4):E572-82.
    View in: PubMed
    Score: 0.389
  47. Novel MED12 gene somatic mutations in women from the Southern United States with symptomatic uterine fibroids. Mol Genet Genomics. 2015 Apr; 290(2):505-11.
    View in: PubMed
    Score: 0.382
  48. Green tea extract inhibition of human leiomyoma cell proliferation is mediated via catechol-O-methyltransferase. Gynecol Obstet Invest. 2014; 78(2):109-18.
    View in: PubMed
    Score: 0.373
  49. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids. Reprod Sci. 2014 Sep; 21(9):1108-19.
    View in: PubMed
    Score: 0.372
  50. 1,25-dihydroxyvitamin d3 reduces extracellular matrix-associated protein expression in human uterine fibroid cells. Biol Reprod. 2013 Dec; 89(6):150.
    View in: PubMed
    Score: 0.361
  51. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Semin Reprod Med. 2013 Sep; 31(5):370-9.
    View in: PubMed
    Score: 0.351
  52. Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013 Sep; 28(9):2398-406.
    View in: PubMed
    Score: 0.349
  53. Vitamin D3 inhibits expression and activities of matrix metalloproteinase-2 and -9 in human uterine fibroid cells. Hum Reprod. 2013 Sep; 28(9):2407-16.
    View in: PubMed
    Score: 0.349
  54. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod. 2012 Apr; 86(4):116.
    View in: PubMed
    Score: 0.321
  55. Medical treatment of uterine leiomyoma. Reprod Sci. 2012 Apr; 19(4):339-53.
    View in: PubMed
    Score: 0.318
  56. Adipocytes enhance the proliferation of human leiomyoma cells via TNF-a proinflammatory cytokine. Reprod Sci. 2011 Dec; 18(12):1186-92.
    View in: PubMed
    Score: 0.313
  57. Vitamin D inhibits proliferation of human uterine leiomyoma cells via catechol-O-methyltransferase. Fertil Steril. 2011 Jan; 95(1):247-53.
    View in: PubMed
    Score: 0.286
  58. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol. 2010 Mar; 202(3):289.e1-9.
    View in: PubMed
    Score: 0.274
  59. Antiproliferative and proapoptotic effects of epigallocatechin gallate on human leiomyoma cells. Fertil Steril. 2010 Oct; 94(5):1887-93.
    View in: PubMed
    Score: 0.270
  60. Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest. 2009; 68(1):19-32.
    View in: PubMed
    Score: 0.260
  61. Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010 Jan; 93(1):239-50.
    View in: PubMed
    Score: 0.256
  62. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am J Obstet Gynecol. 2008 Aug; 199(2):156.e1-8.
    View in: PubMed
    Score: 0.244
  63. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008 Aug; 22(4):589-601.
    View in: PubMed
    Score: 0.242
  64. Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007 Oct; 92(10):3949-57.
    View in: PubMed
    Score: 0.231
  65. Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids. J Soc Gynecol Investig. 2006 Dec; 13(8):542-50.
    View in: PubMed
    Score: 0.220
  66. Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest. 2007; 63(2):61-70.
    View in: PubMed
    Score: 0.217
  67. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006 Sep; 86(3):686-93.
    View in: PubMed
    Score: 0.216
  68. Hormonal regulation of catechol-O-methyl transferase activity in women with uterine leiomyomas. Fertil Steril. 2006 Jul; 86(1):259-62.
    View in: PubMed
    Score: 0.213
  69. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006 Jul-Aug; 12(4):385-400.
    View in: PubMed
    Score: 0.211
  70. Catechol-O-methyltransferase polymorphism is associated with increased uterine leiomyoma risk in different ethnic groups. J Soc Gynecol Investig. 2006 Feb; 13(2):136-44.
    View in: PubMed
    Score: 0.209
  71. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004 Nov; 191(5):1621-31.
    View in: PubMed
    Score: 0.191
  72. Management of Uterine Fibroids and Sarcomas: The Palermo Position Paper. Gynecol Obstet Invest. 2024; 89(2):73-86.
    View in: PubMed
    Score: 0.182
  73. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. Am J Obstet Gynecol. 2024 Feb; 230(2):237.e1-237.e11.
    View in: PubMed
    Score: 0.178
  74. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells. 2022 Nov 27; 11(23).
    View in: PubMed
    Score: 0.167
  75. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. Lancet. 2022 09 17; 400(10356):896-907.
    View in: PubMed
    Score: 0.165
  76. Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid. Reprod Sci. 2022 09; 29(9):2607-2619.
    View in: PubMed
    Score: 0.161
  77. Adverse childhood experiences and health-related quality of life among women undergoing hysterectomy for uterine leiomyoma. Am J Obstet Gynecol. 2022 08; 227(2):351-353.e5.
    View in: PubMed
    Score: 0.161
  78. A Call-to-Action for Clinicians to Implement Evidence-Based Best Practices When Caring for Women with Uterine Fibroids. Reprod Sci. 2022 04; 29(4):1188-1196.
    View in: PubMed
    Score: 0.159
  79. Simvastatin inhibits stem cell proliferation in human leiomyoma via TGF-ß3 and Wnt/ß-Catenin pathways. J Cell Mol Med. 2022 03; 26(5):1684-1698.
    View in: PubMed
    Score: 0.158
  80. Evaluation of Hedgehog Pathway Inhibitors as a Therapeutic Option for Uterine Leiomyosarcoma Using the Xenograft Model. Reprod Sci. 2022 03; 29(3):781-790.
    View in: PubMed
    Score: 0.155
  81. Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacol Res. 2021 10; 172:105856.
    View in: PubMed
    Score: 0.153
  82. Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients. Sci Rep. 2021 04 30; 11(1):9371.
    View in: PubMed
    Score: 0.150
  83. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells. Cells. 2020 12 31; 10(1).
    View in: PubMed
    Score: 0.147
  84. The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis. Curr Opin Endocrinol Diabetes Obes. 2020 12; 27(6):380-387.
    View in: PubMed
    Score: 0.146
  85. Summary of the Proceedings of the Basic Science of Uterine Fibroids Meeting: New Developments February 28, 2020. F S Sci. 2021 02; 2(1):88-100.
    View in: PubMed
    Score: 0.145
  86. Non-hormonal mediators of uterine fibroid growth. Curr Opin Obstet Gynecol. 2020 10; 32(5):361-370.
    View in: PubMed
    Score: 0.144
  87. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
    View in: PubMed
    Score: 0.141
  88. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020 03 01; 105(3).
    View in: PubMed
    Score: 0.138
  89. Uterine fibroids in menopause and perimenopause. Menopause. 2020 02; 27(2):238-242.
    View in: PubMed
    Score: 0.138
  90. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene. 2019 07; 38(27):5356-5366.
    View in: PubMed
    Score: 0.131
  91. 1,25 Dihydroxyvitamin D3 Enhances the Antifibroid Effects of Ulipristal Acetate in Human Uterine Fibroids. Reprod Sci. 2019 06; 26(6):812-828.
    View in: PubMed
    Score: 0.127
  92. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas. J Clin Endocrinol Metab. 2018 11 01; 103(11):4283-4292.
    View in: PubMed
    Score: 0.126
  93. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
    View in: PubMed
    Score: 0.126
  94. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018 11; 27(11):1359-1367.
    View in: PubMed
    Score: 0.125
  95. A Preliminary Study: Human Fibroid Stro-1+/CD44+ Stem Cells Isolated From Uterine Fibroids Demonstrate Decreased DNA Repair and Genomic Integrity Compared to Adjacent Myometrial Stro-1+/CD44+ Cells. Reprod Sci. 2019 05; 26(5):619-638.
    View in: PubMed
    Score: 0.123
  96. Non-coding RNAs: an important regulatory mechanism in pathogenesis of uterine fibroids. Fertil Steril. 2018 05; 109(5):802-803.
    View in: PubMed
    Score: 0.122
  97. Uterine Fibroids: Bridging Genomic Defects and Chronic Inflammation. Semin Reprod Med. 2017 11; 35(6):494-498.
    View in: PubMed
    Score: 0.118
  98. Oxidative stress: a key regulator of leiomyoma cell survival. Fertil Steril. 2017 06; 107(6):1387-1394.e1.
    View in: PubMed
    Score: 0.114
  99. Developmental Exposure to Endocrine Disruptors Expands Murine Myometrial Stem Cell Compartment as a Prerequisite to Leiomyoma Tumorigenesis. Stem Cells. 2017 03; 35(3):666-678.
    View in: PubMed
    Score: 0.110
  100. Berberine Inhibits Uterine Leiomyoma Cell Proliferation via Downregulation of Cyclooxygenase 2 and Pituitary Tumor-Transforming Gene 1. Reprod Sci. 2017 07; 24(7):1005-1013.
    View in: PubMed
    Score: 0.110
  101. Hypovitaminosis D and high serum transforming growth factor beta-3: important biomarkers for uterine fibroids risk. Fertil Steril. 2016 12; 106(7):1648-1649.
    View in: PubMed
    Score: 0.110
  102. Endocrine-disrupting chemicals and uterine fibroids. Fertil Steril. 2016 09 15; 106(4):967-77.
    View in: PubMed
    Score: 0.108
  103. Role of vitamin D in uterine fibroid biology. Fertil Steril. 2015 Sep; 104(3):698-706.
    View in: PubMed
    Score: 0.100
  104. Stro-1/CD44 as putative human myometrial and fibroid stem cell markers. Fertil Steril. 2015 Jul; 104(1):225-34.e3.
    View in: PubMed
    Score: 0.099
  105. Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study. Am J Obstet Gynecol. 2015 Aug; 213(2):196.e1-8.
    View in: PubMed
    Score: 0.098
  106. Berberine inhibits the proliferation of human uterine leiomyoma cells. Fertil Steril. 2015 Apr; 103(4):1098-106.
    View in: PubMed
    Score: 0.098
  107. Nicotinamide adenine dinucleotide phosphate oxidase is differentially regulated in normal myometrium versus leiomyoma. Reprod Sci. 2014 Sep; 21(9):1145-52.
    View in: PubMed
    Score: 0.091
  108. Uterine fibroids are characterized by an impaired antioxidant cellular system: potential role of hypoxia in the pathophysiology of uterine fibroids. J Assist Reprod Genet. 2013 Jul; 30(7):969-74.
    View in: PubMed
    Score: 0.087
  109. Towards non-surgical therapy for uterine fibroids: catechol-O-methyl transferase inhibitor shrinks uterine fibroid lesions in the Eker rat model. Hum Reprod. 2011 Nov; 26(11):3008-18.
    View in: PubMed
    Score: 0.077
  110. 1,25-Dihydroxyvitamin D3 reduces TGF-beta3-induced fibrosis-related gene expression in human uterine leiomyoma cells. J Clin Endocrinol Metab. 2011 Apr; 96(4):E754-62.
    View in: PubMed
    Score: 0.074
  111. Potential nonhormonal therapeutics for medical treatment of leiomyomas. Semin Reprod Med. 2004 May; 22(2):121-30.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.